Healthcare Value Capital 13F annual report
Healthcare Value Capital is an investment fund managing more than $46.2 million ran by Thomas Deschamps. There are currently 18 companies in Mr. Deschamps’s portfolio. The largest investments include Gilead Sciences and Glaxosmithkline plc, together worth $9.15 million.
$46.2 million Assets Under Management (AUM)
As of 9th August 2021, Healthcare Value Capital’s top holding is 75,000 shares of Gilead Sciences currently worth over $5.17 million and making up 11.2% of the portfolio value.
Relative to the number of outstanding shares of Gilead Sciences, Healthcare Value Capital owns more than approximately 0.1% of the company.
In addition, the fund holds 100,000 shares of Glaxosmithkline plc worth $3.98 million, whose value grew 17.7% in the past six months.
The third-largest holding is Pfizer worth $3.92 million and the next is Alkermes plc worth $3.68 million, with 150,000 shares owned.
Currently, Healthcare Value Capital's portfolio is worth at least $46.2 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Healthcare Value Capital
The Healthcare Value Capital office and employees reside in Woodcliff Lake, New Jersey. According to the last 13-F report filed with the SEC, Thomas Deschamps serves as the Managing Director, Portfolio Manager at Healthcare Value Capital.
Recent trades
In the most recent 13F filing, Healthcare Value Capital revealed that it had opened a new position in
MiMedx Inc and bought 125,000 shares worth $1.56 million.
This means they effectively own approximately 0.1% of the company.
MiMedx Inc makes up
3.5%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Alkermes plc by buying
50,000 additional shares.
This makes their stake in Alkermes plc total 150,000 shares worth $3.68 million.
Alkermes plc dropped approximately 0.1% in the past year.
On the other hand, there are companies that Healthcare Value Capital is getting rid of from its portfolio.
Healthcare Value Capital closed its position in Aurinia Pharmaceuticals Inc on 16th August 2021.
It sold the previously owned 100,000 shares for $1.3 million.
One of the smallest hedge funds
The two most similar investment funds to Healthcare Value Capital are Covalent Partners and Encap Energy Capital Fund Viii Co-investors, L.P.. They manage $46.2 million and $46.4 million respectively.
Thomas Deschamps investment strategy
Healthcare Value Capital’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 96.6% of
the total portfolio value.
The fund focuses on investments in the United States as
66.7% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are large-cap stocks.
Stocks with a size of more than $10 billion in market cap make up
33% of the total holdings value.
On the other hand, small-cap stocks make up 11.1% of the portfolio.
The average market cap of the portfolio companies is close to $53.7 billion.
The complete list of Healthcare Value Capital trades based on 13F SEC filings
These positions were updated on August 16th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Gilead Sciences, Inc. |
No change
75,000
|
$5,165,000 | 11.17% |
| Glaxosmithkline plc |
No change
100,000
|
$3,982,000 | 8.61% |
| Pfizer Inc. |
No change
100,000
|
$3,916,000 | 8.47% |
| Alkermes plc |
50.00%
150,000
|
$3,678,000 | 7.95% |
| Bristol-Myers Squibb Co. |
100.00%
50,000
|
$3,341,000 | 7.23% |
| Merck & Co Inc |
100.00%
40,000
|
$3,111,000 | 6.73% |
| Astrazeneca plc |
100.00%
50,000
|
$2,995,000 | 6.48% |
| Clovis Oncology Inc |
11.11%
500,000
|
$2,900,000 | 6.27% |
| Ironwood Pharmaceuticals Inc |
No change
200,000
|
$2,574,000 | 5.57% |
| Amryt Pharma plc |
28.57%
200,000
|
$2,426,000 | 5.25% |
| Collegium Pharmaceutical Inc |
No change
100,000
|
$2,364,000 | 5.11% |
| Antares Pharma Inc |
No change
500,000
|
$2,180,000 | 4.71% |
| Tyme Technologies Inc |
No change
1,500,000
|
$1,890,000 | 4.09% |
| VYNE Therapeutics Inc. |
12.50%
450,000
|
$1,580,000 | 3.42% |
| Greenlane Holdings Inc |
40.00%
350,000
|
$1,565,000 | 3.38% |
| MiMedx Group, Inc |
Opened
125,000
|
$1,564,000 | 3.38% |
| Aurinia Pharmaceuticals Inc |
Closed
100,000
|
$1,299,000 | |
| Adamas Pharmaceuticals Inc |
No change
100,000
|
$528,000 | 1.14% |
| Gamida Cell Ltd |
50.00%
75,000
|
$481,000 | 1.04% |
| No transactions found | |||
| Showing first 500 out of 19 holdings | |||
Hedge funds similar to Healthcare Value Capital
- Cigna
- Cambrian Capital Partnership
- Castlelake L.P.
- Zpr Investment Management
- Security Benefit Life Insurance Co ks/
- Sagard Capital Partners Management Corp
- Encap Energy Capital Fund Viii Co-investors, L.P.
- Covalent Partners
- Norwest Venture Partners Xii, L.P.
- Thompson Davis & Co., Inc
- Tokio Marine & Nichido Fire Insurance Co., Ltd
- Aisling Capital
- Pacific Life Insurance Company
- Portland Ltd